Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triiodothyronine in heart failure with reduced ejection fraction and low T3
ISRCTN11121053Phase 3Recruiting
- Sponsor
- Newcastle Hospitals NHS Foundation Trust
- Start
- May 2026
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in heart failure with reduced ejection fraction (HFrEF) comparing Liothyronine with Placebo (2 arms). Primary endpoint: 6-minute walk test distance. Started May 2026; status: recruiting.
02
Drugs
liothyronine
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on ISRCTN11121053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN11121053.